Quanterix Stock Price, News & Analysis

Quanterix (NASDAQ: QTRX), a biomarker detection company, has announced a cooperation agreement with Kent Lake Capital. The key terms include: appointment of a new independent director by December 1, 2025, through a joint search process involving both parties, plans to declassify the Board at the 2025 Annual Meeting, and adoption of a majority voting standard for uncontested director elections.

Kent Lake has agreed to withdraw its director nominations and support the Board's candidates, along with accepting standstill and voting commitments until 30 days before Quanterix's 2027 Annual Meeting nomination deadline. The agreement aims to maintain focus on company strategy and maximize benefits from the Akoya transaction.

Quanterix (NASDAQ: QTRX) has launched two first-to-market phospho-tau assays: p-Tau 205 and p-Tau 212 for Alzheimer's disease research. These novel assays, developed on the company's Simoa® platform, enable precise detection of tau phosphorylation sites associated with early-stage Alzheimer's disease.

The announcement coincides with the company's presence at AAIC 2025, where its Simoa® technology is featured in over 55 presentations. Following the recent Akoya Biosciences acquisition, Quanterix now combines fluid-based biomarker detection with spatial proteomics capabilities, offering researchers comprehensive tools for neurodegenerative disease research.

Quanterix (NASDAQ: QTRX), a biomarker detection company, has granted inducement restricted stock units (RSUs) to 20 new employees who joined through the Akoya Biosciences acquisition. The equity awards, totaling 267,269 RSU shares, were approved on July 8, 2025, under Nasdaq Rule 5635(c)(4).

The RSUs will fully vest after one year from the grant date, contingent on continued employment with Quanterix or its subsidiaries. These grants were made as part of the employees' compensation packages and served as inducements for their employment acceptance.

Quanterix (NASDAQ: QTRX) has completed its acquisition of Akoya Biosciences, creating an integrated platform for biomarker detection across blood and tissue. The transaction involved issuing 7.8 million shares of Quanterix common stock and $20 million in cash to Akoya equity holders.

The merger expands Quanterix's addressable market from $1 billion to $5 billion, focusing on neurology, oncology, and immunology markets. The combined company maintains $163 million in cash post-transaction and targets profitability by 2026. As part of the deal, Scott Mendel and Dr. Myla Lai-Goldman join Quanterix's Board, replacing Martin D. Madaus and Sarah Hlavinka.

Quanterix Corporation (NASDAQ: QTRX) announced that its HD-X Simoa Immunoassay Analyzer received Class 1 Medical Device registration in South Korea through HS Biosystems. The company has established new global collaborations with major laboratories including ARUP Laboratories, Neurogen Biomarking, NSW Health Pathology, and Rede D'Or. The Simoa platform enables ultrasensitive biomarker detection in blood for early disease detection, particularly for Alzheimer's disease through P-tau217 testing. The technology uniquely serves multiple purposes from research discovery to clinical trials and diagnostic testing. Notable implementations include ARUP's blood test for P-tau217 using Quanterix's SP-X platform and Neurogen's at-home blood biomarker collection test, expanding accessibility to early Alzheimer's detection and treatment options.

Kent Lake PR LLC, holding 6.9% of Quanterix Corporation (NASDAQ: QTRX) stock, has publicly criticized the company for failing to schedule its 2025 Annual Meeting, despite over a year passing since the last meeting on June 3, 2024. Kent Lake alleges this delay is a deliberate tactic by the Board to avoid shareholder accountability and push through the controversial Akoya merger without proper shareholder input. The activist investor suggests the Board is attempting to dilute existing shareholders' voting power by delaying until after the Akoya merger closes. Kent Lake demands immediate scheduling of the annual meeting and proposes including a board declassification measure, citing poor stock performance since the 2017 IPO under the current board structure.

Quanterix Corporation (NASDAQ: QTRX), a biomarker detection technology company, announced that President and CEO Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida. The presentation is scheduled for June 9th, 2025, at 1:20 p.m. ET. The company will also conduct one-on-one meetings with institutional investors during the event. A live webcast of the presentation will be available through the Investors section of Quanterix's website, with a replay option available for a limited time after the conference.

Kent Lake, holding 6.9% of Quanterix (QTRX) shares, responds to developments in the proposed merger with Akoya Biosciences (AKYA). The key points include: 1. Akoya received an unsolicited all-cash offer of $1.40 per share, representing a 22% premium over both Akoya's 30-day VWAP and Quanterix's implied offer. 2. Quanterix's amended merger terms, which bypass shareholder voting, include $20 million in cash and 8.4 million new shares. 3. Quanterix trades at $4.75 per share, below its net cash position, with a negative enterprise value of $80 million. Kent Lake strongly opposes any increase in Quanterix's offer, citing concerns about value destruction, balance sheet risks, and management's unrealistic break-even projections for 2026, especially given the combined companies' current $80 million burn rate.

Quanterix (QTRX) reported Q1 2025 financial results with revenue of $30.3M, down 5% YoY. The company posted a net loss of $20.5M compared to $11.2M loss in prior year. Key highlights include a new early-access program making Simoa® ONE assay kits compatible with over 20,000 flow cytometers, expanding their market reach significantly. The company is implementing $30M in annual cost reductions targeting positive cash flow by 2026. Quanterix ended Q1 with $269.5M in cash and securities. For 2025, the company expects revenues of $120-130M (5-13% YoY decline) and GAAP gross margin of 55-59%. The amended merger with Akoya Biosciences reduced equity value by 67% and increased Quanterix shareholder ownership to 84%, with closing expected in June 2025.